In vitro, EGCG has been shown to inhibit growth by increasing the percentage of cells at the G0/G1 phase of the cell cycle (Fujiki et al., 2017) and inhibit epithelial-mesenchymal transition and migration via downregulation of HIF-1α, VEGF, pAkt/ERK, COX-2 and vimentin in A549 lung cancer cell (Shi et al., 2015). The gene discussed is VEGFA; the disease is lung cancer.